



OPEN ACCESS

EDITED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Xianming Xu,
xuxm11@163.com

SPECIALTY SECTION
This article was submitted to Obstetric
and Pediatric Pharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 18 June 2022
ACCEPTED 15 August 2022
PUBLISHED 23 September 2022

CITATION
Cheng D-c, Su Y, Li F and Xu X (2022),
Corrigendum: Insulin treatment of
hypertriglyceridemia during pregnancy.
Front. Pharmacol. 13:972477.
doi: 10.3389/fphar.2022.972477

COPYRIGHT
© 2022 Cheng, Su, Li and Xu. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Corrigendum: Insulin treatment of hypertriglyceridemia during pregnancy

De-cui Cheng, Yao Su, Feifei Li and Xianming Xu*

Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China

KEYWORDS

insulin, hypertriglyceridemia, pregnancy, hypercholesterolemia, fetus

A Corrigendum on Insulin treatment of hypertriglyceridemia during pregnancy

by Cheng D-c Su Y, Li F and Xu X (2022). *Front. Pharmacol.* 12:785756. doi: 10.3389/fphar.2021.785756

In the published article, there was an error in the Affiliation. Instead of “Department of Obstetrics and Gynecology, Jiao Tong University School of Medicine, Shanghai, China,” it should be “Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China.”

Additionally, a correction has been made to **Methods** section, paragraph 1. The last sentence previously stated “This research was registered with the Chinese Clinical Trial Registry (ChiCTR2000036575).” However the correct sentence is “This research was funded by the Chinese Clinical Trial Registry (ChiCTR2000036575).” The **Conflict of Interest** statement has also been updated to reflect this.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Conflict of interest

This study received funding from Chinese Clinical Trial Registry (ChiCTR2000036575). The funder had the following involvement with the study: service charge of postgraduates collecting data and also for publishing fee.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.